<DOC>
	<DOCNO>NCT00932620</DOCNO>
	<brief_summary>Both simvastatin 40 mg simvastatin/ezetimibe 10/10 mg result low-density lipoprotein cholesterol ( LDL-C ) reduction approximately magnitude . However , differential effect two treatment option small dense LDL-C ( sdLDL-C ) concentration assess . The aim present study compare effect simvastatin 40 mg versus simvastatin/ezetimibe 10/10 mg sdLDL-C concentration . The primary efficacy endpoint change LDL subfraction profile ( i.e . mean LDL particle size , sdLDL-C level ) 3 month treatment initiation .</brief_summary>
	<brief_title>Comparison Simvastatin Versus Simvastatin/Ezetimibe Small Dense Low -Density Lipoprotein ( LDL )</brief_title>
	<detailed_description>Hypercholesterolemia major risk factor atherosclerosis coronary heart disease ( CHD ) . [ 1 ] Epidemiological clinical study demonstrate aggressive lower low-density lipoprotein cholesterol ( LDL-C ) reduce morbidity mortality patient without CHD . [ 1-3 ] LDL consist heterogeneous population particle respect size , density chemical composition . Several study show small , dense LDL ( sdLDL ) particles atherogenic large , buoyant one [ 4 , 5 ] thus associate increase risk coronary artery disease [ 6 ] stroke . [ 7 ] Statins , mainstay lipid lower therapy , achieve significant reduction LDL-C level suggest low LDL subfractions , possibly result statin-induced stimulation LDL-receptor-mediated catabolism . [ 8 ] Moreover , several study show abnormality LDL subfraction profile amenable correction statin . [ 9 ] Ezetimibe monotherapy also find significantly reduce concentration LDL subfractions . [ 10 ] The combination ezetimibe low dose statin result similar LDL-C lowering compare high dose statin . A recent study demonstrate ezetimibe/simvastatin combination effective ezetimibe simvastatin monotherapy reduce atherogenic lipoprotein subfractions patient primary hypercholesterolemia . [ 11 ] However , study ezetimibe/simvastatin combination potent reduce LDL-C level compare either monotherapy . [ 11 ] In another study , addition ezetimibe patient already receive atorvastatin decrease LDL-C value exclusively reduce concentration large , buoyant LDL subfractions . [ 12 ] It far unknown whether high-dose statin would reduce sdLDL-C level low-dose statin plus ezetimibe therapy degree LDL-C lowering . Both simvastatin 40 mg simvastatin/ezetimibe 10/10 mg result LDL-C reduction approximately magnitude . [ 13,14 ] However , differential effect two treatment option sdLDL-C concentration assess . Study design Randomized , open label study . Aim study The aim present study compare effect simvastatin 40 mg versus simvastatin/ezetimibe 10/10 mg sdLDL-C concentration . Materials Methods Study population Consecutive patient primary hypercholesterolemia ( n=100 ) attend Outpatient Lipid Obesity Clinic University Hospital Ioannina , Ioannina , Greece participate present study . All subject receive dietary instruction accord National Cholesterol Education Program Adult Treatment Panel III ( NCEP-ATP III ) clinical nutritionist . If LDL-C still recommend level 3 month appropriate lifestyle change , patient randomly allocate open-label simvastatin 40 mg ( n=50 ) simvastatin/ezetimibe 10/10 mg ( n=50 ) daily . Enrollment complete period 1 year . Follow-up visit schedule 3 month treatment initiation . The study protocol approve Ethics Committee University Hospital Ioannina participant ask give write informed consent . Laboratory measurement Blood analysis carry overnight fast ( 12 hour ) include : - Glucose , insulin , creatinine , uric acid , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyl transpeptidase ( γ-GT ) , alkaline phosphatase ( ALP ) - Total cholesterol ( TC ) , high-density lipoprotein cholesterol ( HDL-C ) triglyceride level , whereas LDL-C level assess use Friedewald equation ( LDL-C = TC-HDL-C-triglycerides/5 ) - high-sensitivity C-reaction protein ( hs-CRP ) level - Apolipoproteins A-I , A-II , A-V , B , E , C-II , C-III , lipoprotein ( ) [ Lp ( ) ] - Lipoprotein-associated phospholipase A2 ( Lp-PLA2 ) activity plasma Methods LDL subclass analysis Electrophoresis perform use high resolution 3 % polyacrylamide tube gel Lipoprint LDL System ( Quantimetrix , Redondo Beach , CA ) accord manufacturer 's instruction . [ 16 , 17 , 18 ] Briefly , 25 μl sample mixed 200 μl Lipoprint Loading Gel place upon upper part 3 % polyacrylamide gel . After 30 min photopolymerization room temperature , electrophoresis perform 60 min 3 mA gel tube . Each electrophoresis chamber involve 2 quality control ( sample provide manufacturer ) . For quantification , scan perform ScanMaker 8700 digital scanner ( Mikrotek Co , USA ) iMac personal computer ( Apple Computer Inc , USA ) . After scan , electrophoretic mobility ( Rf ) area curve ( AUC ) calculate qualitatively quantitatively Lipoprint LDL system Template Lipoware software ( Quantimetrix Co , Redondo Beach , CA ) , respectively . The LDL subfraction calculate use Rf low-density lipoprotein ( VLDL ) fraction ( Rf 0.0 ) HDL fraction ( Rf 1.0 ) . LDL distribute Rf 0.32 Rf 0.64 7 band , whose Rfs 0.32 , 0.38 , 0.45 , 0.51 , 0.56 , 0.6 0.64 ( LDL1 LDL7 , respectively ) . LDL1 LDL2 define large , buoyant LDL LDL3 LDL7 define sd-LDL . The cholesterol concentration ( mg/dl ) LDL subfraction determine multiply relative AUC subfraction TC concentration sample ( TC concentration sample measure independently ) . The proportion sd-LDL-cholesterol ( sd-LDL % ) define percentage LDL-cholesterol carry sd-LDL ( i.e . band 3 7 ) . LDL peak particle diameter ( LDL-PPD ) ( nm ) determine use Rf high peak LDL band accord follow equation propose : LDL-PPD = ( 1.429-Rf ) *25 . Moreover , Lipoprint LDL System provide mean LDL particle size ( nm ) use size 26.8 nm cut-off point classify individual phenotypes A ( absence sd-LDL particle ) non-A ( presence sd-LDL particle ) . Measurement plasma Lp-PLA2 activity Lp-PLA2 activity total plasma , apo B-depleted plasma , sedimentation apo B-containing lipoprotein dextran sulfate-magnesium chloride ( HDL-Lp-PLA2 activity ) well lipoprotein subfractions , determine trichloroacetic acid precipitation procedure use [ 3H ] -platelet-activating factor ( PAF ) ( 100 μM final concentration ) substrate . [ 16 ] The reaction perform 10 min 37°C Lp-PLA2 activity express nmol PAF degrade per min per ml plasma mg LDL subfraction protein . The non-HDL-Lp-PLA2 activity calculate subtract HDL-Lp-PLA2 activity total plasma enzyme activity . Lp-PLA2 specific activity express ratio enzyme activity enzyme mass ( nmol/ng/min ) . Serum apolipoproteins measurement Serum apolipoproteins A-I , A-II , AV , B , E , C-II , C-III Lp ( ) measure immunonephelometry Behring Nephelometer BN ProSpec ( Dade-Behring , Lieberbach , Germany ) . Determination plasma hs-CRP level Plasma concentration CRP measure high sensitivity immunonephelometric assay ( Beckman Instruments , Fullerton , CA ) . The reference range assay 1.0 80 mg/l . The detection limit 1.0 mg/l . Routine laboratory determination Routine laboratory determination carry automated chemical analysis laboratory University Hospital Ioannina use Olympus AU 600 analyzer ( Olympus Diagnostica GmbH , Hamburg , Germany ) . Glucose measure hexokinase method serum insulin level AxSYM Insulin assay , base Microparticle Enzyme Immunoassay technology ( Abbott Laboratories , Diagnostic Division , Abbott Park , IL , USA ) . Statistical analysis All parameter check normality Kolmogorov-Smirnov test non-normal-distributed variable log-transformed . Linear regression analysis use assessment relationship study variable , whereas multivariate analysis use determination independent predictor study parameter change . The paired-samples t-test use assess effect treatment group . Analysis covariance ( ANOVA ) , adjust baseline value , use comparison treatment group . Significance define p &lt; 0.05 Bonferroni correction apply case multiple comparison . All analysis carry SPSS 13.0 ( SPSS Inc. , 1989-2004 , Chicago , IL ) . It estimate sample size 90 would give 94 % power detect 15 % difference reduction sdLDL-C concentration 2 group 2-sided alpha 0.05 . We include 100 patient allow drop-out rate ~10 % .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>LDLC level recommend National Cholesterol Education Program Adult Treatment Panel III ( NCEPATP III ) base patient risk factor follow 3month period lifestyle change . Triglycerides &gt; 500 mg/dL , renal disease ( serum creatinine level &gt; 1.6 mg/dL ) , hypothyroidism [ thyroid stimulate hormone ( TSH ) &gt; 5 IU/mL ] liver disease ( ALT and/or AST level &gt; 3fold upper limit normal 2 consecutive measurement ) . Patients hypertension include study stable medication least 3 month blood pressure adequately control ( change treatment make study period ) . Patients currently take lipid lower drug stop less 4 week study entry exclude</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>statin</keyword>
	<keyword>simvastatin</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>LDL particle</keyword>
</DOC>